Fulcrum Therapeutics (FULC) Total Current Liabilities (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Total Current Liabilities data on file, last reported at $9.9 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $9.9 million, up 21.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.9 million (up 21.78% YoY), and the FY2025 annual result was $13.0 million, up 18.15% from the prior year.
• Total Current Liabilities declined to $9.9 million in Q1 2026 per FULC's latest filing, from $13.0 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $22.1 million in Q2 2022 and troughed at $8.1 million in Q1 2025.
• A 5-year average of $13.5 million and a median of $13.7 million in 2023 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2026: Total Current Liabilities tumbled 33.08% in 2023, then rose 21.78% in 2026.
• A 5-year view of Total Current Liabilities shows it stood at $16.7 million in 2022, then retreated by 18.24% to $13.7 million in 2023, then slipped by 19.24% to $11.0 million in 2024, then increased by 18.15% to $13.0 million in 2025, then declined by 24.4% to $9.9 million in 2026.
• Business Quant data shows FULC's Total Current Liabilities at $9.9 million in Q1 2026, $13.0 million in Q4 2025, and $11.6 million in Q3 2025.